FDA Should Create “Clearly Articulated Pathway” For Patient-Centered Research – Pfizer’s Lewis-Hall
This article was originally published in The Pink Sheet Daily
Pfizer CMO Freda Lewis-Hall acknowledged FDA’s current activities to promote patient-centered research, but called on the agency to lead in developing guidance to help industry be more proactive in incorporating patients into its research.
You may also be interested in...
COPD Patient-Reported Outcome Questionnaire Is Early Example of FDA Drug Development Tool “Approval” Process
FDA finalizes the "qualification process for drug development tools." The topic won't get as much attention as Breakthrough Therapy or Accelerated Approval, but the head of the drug center thinks this is a very big deal. A COPD outcomes assessment is an early example of the process in action.
Work needs to be done to allow for the use of social media to support content validity of patient-reported outcomes, but one FDA endpoints reviewer says there is a place for social media to work alongside traditional methods of validating PROs.
Drug Development Needs “Clean-Slate Think” To Involve Patients All Along The Way – Pfizer’s Lewis-Hall
Drug companies and other stakeholders should collaborate on developing a “clear framework” for patient engagement, Freda Lewis-Hall says at ISPOR.